Mai Alalawi
Overview
Explore the profile of Mai Alalawi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
54
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Al Sulaiman K, Aljuhani O, Korayem G, Altebainawi A, Alharbi A, Alalawi M, et al.
Int J Gen Med
. 2024 Dec;
17:5611-5622.
PMID: 39628980
Purpose: To evaluate the effectiveness and safety of anticoagulation regimens in COVID-19 critically ill patients with new-onset Atrial fibrillation (Afib) during their intensive care unit (ICU) stays. Methods: A multicenter,...
2.
Almarhabi H, Alharbi A, Alalawi M, Ahamed M, El-Hemaidi I, Damfu N
J Infect Public Health
. 2024 Sep;
17(10):102526.
PMID: 39226796
Patients with hematological malignancies are at increased risk of persistent coronavirus disease 2019 (COVID-19) infection, a unique clinical condition, for which the optimal treatment is unknown. Here we report a...
3.
Al Sulaiman K, Aljuhani O, Korayem G, AlFaifi M, Alharthi A, Alshehri A, et al.
Infect Drug Resist
. 2024 Jul;
17:3161-3171.
PMID: 39050827
Background: There is increasing evidence suggesting that ABO blood type may play a role in the immunopathogenesis of COVID-19 infection. In addition to ABO blood type, the Rhesus (Rh) factor...
4.
Aljuhani O, Korayem G, Altebainawi A, AlMohammady D, Alfahed A, Altebainawi E, et al.
BMC Infect Dis
. 2024 Feb;
24(1):189.
PMID: 38350878
Background: Dexamethasone usually recommended for patients with severe coronavirus disease 2019 (COVID-19) to reduce short-term mortality. However, it is uncertain if another corticosteroid, such as methylprednisolone, may be utilized to...
5.
Alalawi M, Alsalloum M, Garwan Y, Abuzeid M, Alalawi H, Eljaaly K, et al.
PLoS One
. 2024 Jan;
19(1):e0296432.
PMID: 38166119
Background: Vaccine hesitancy is a major obstacle to the large efforts made by governments and health organizations toward achieving successful COVID-19 vaccination programs. Healthcare worker's (HCWs) acceptance or refusal of...
6.
Al Sulaiman K, Aljuhani O, Korayem G, Altebainawi A, Vishwakarma R, AlFaifi M, et al.
Clin Appl Thromb Hemost
. 2023 Dec;
29:10760296231218216.
PMID: 38073058
The use of erythropoietin-stimulating agents (ESAs) as adjunctive therapy in critically ill patients with COVID-19 may have a potential benefit. This study aims to evaluate the effect of ESAs on...
7.
Al Sulaiman K, Aljuhani O, Korayem G, Altebainawi A, Alharbi R, Assadoon M, et al.
BMC Pulm Med
. 2023 Oct;
23(1):392.
PMID: 37848847
No abstract available.
8.
Al Sulaiman K, Korayem G, Aljuhani O, Altebainawi A, Shawaqfeh M, Alarfaj S, et al.
Front Med (Lausanne)
. 2023 Sep;
10:1237903.
PMID: 37692775
Background: Despite insufficient evidence, vitamin D has been used as adjunctive therapy in critically ill patients with COVID-19. This study evaluates the effectiveness and safety of vitamin D as an...
9.
Al Sulaiman K, Aljuhani O, Korayem G, Altebainawi A, Alharbi R, Assadoon M, et al.
BMC Pulm Med
. 2023 Aug;
23(1):315.
PMID: 37641042
Background: Previous studies have shown mortality benefits with corticosteroids in Coronavirus disease-19 (COVID-19). However, there is inconsistency regarding the use of methylprednisolone over dexamethasone in COVID-19, and this has not...
10.
Al Sulaiman K, Aljuhani O, Korayem G, Alnajjar L, Altebainawi A, AlFaifi M, et al.
Clin Appl Thromb Hemost
. 2023 Jun;
29:10760296231177017.
PMID: 37322869
Doxycycline has revealed potential effects in animal studies to prevent thrombosis and reduce mortality. However, less is known about its antithrombotic role in patients with COVID-19. Our study aimed to...